Craft

BeiGene

Stock Price

$146.1

2024-02-15

Market Capitalization

$15.2 B

2024-02-15

Revenue

$1.4 B

FY, 2022

BeiGene Summary

Company Summary

Overview
BeiGene is a life science biotechnology company. It focuses on discovering and developing targeted and immuno-oncology drugs that address unmet medical needs in a variety of cancer indications.
Type
Public
Status
Active
Founded
2010
HQ
Cambridge, MA, US | view all locations
Website
http://www.beigene.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • John V. Oyler

    John V. Oyler, Co-Founder, Chairman, Chief Executive Officer

  • Xiaodong Wang

    Xiaodong Wang, Co-Founder, Chairman of Scientific Advisory Board

    • Xiaobin Wu

      Xiaobin Wu, President, Chief Operating Officer & General Manager of China

    • Anita Wu

      Anita Wu, Chief Commercial Officer, Greater China

    Operating MetricsView all

    Patents Pending

    21

    FY, 2016

    Patents Issued

    8

    FY, 2016

    Registration Phase Products (Oncology)

    25
    3.8%

    FY, 2020

    LocationsView all

    12 locations detected

    • Cambridge, MA HQ

      United States

      55 Cambridge Pkwy #700W

    • Emeryville, CA

      United States

      1900 Powell St #820

    • Fulton, MD

      United States

      8170 Maple Lawn Blvd #160

    • Ridgefield Park, NJ

      United States

      55 Challenger Rd #501Ridgefield

    • San Mateo, CA

      United States

      2955 Campus Dr 2nd Floor

    • Beijing, Beijing Shi

      China

      6 Jianguomenwai Avenue, Central International Trade Center 22nd Floor, Tower D Chaoyang District

    and 6 others

    BeiGene Financials

    Summary Financials

    Revenue (Q3, 2023)
    $781.3M
    Gross profit (Q3, 2023)
    $685.0M
    Net income (Q3, 2023)
    $215.4M
    Cash (Q3, 2023)
    $3.1B
    EBIT (Q3, 2023)
    ($134.0M)
    Enterprise value
    $14.8B

    Footer menu